Patient characteristics
| Patient characteristics | N=148 |
| Age (years) | |
| Mean±SD | 67±9.6 |
| Range (min–max) | 33–83 |
| Sex, n (%) | |
| Male | 111 (75) |
| Female | 37 (25) |
| Tumour sample origin, n (%) | |
| Endoscopic biopsy from primary tumour | 40 (27.0) |
| Surgical specimen from primary tumour | 96 (64.8) |
| Surgical specimen from metastases | 12 (8.1) |
| First diagnosed with metastases, n (%) | |
| Yes | 86 (58.11) |
| No | 62 (41.89) |
| Lauren's histological type, n (%) | |
| Intestinal | 75 (50.7) |
| Diffuse | 42 (28.3) |
| Undetermined | 31 (20.9) |
| Localisation of the metastases*, n (%) | |
| Liver | 57 (38.5) |
| Lung | 17 (11.5) |
| Thoracic lymph nodes | 15 (10.1) |
| Abdominal lymph nodes | 90 (60.8) |
| Peritoneal spread | 48 (32.4) |
| Other (bone, ovarian, central nervous system) | 14 (9.5) |
| Treatment, n (%) | |
| Chemotherapy | 121 (81.8) |
| Monotherapy | 11 (7.4) |
| Platinum/fluoropyrimidines doublet | 34 (23.0) |
| Platinum/taxane doublet | 29 (19.6) |
| Other doublets | 2 (1.4) |
| Platinum-based triplet | 25 (16.9) |
| Trastuzumab+chemotherapy | 20 (13.5) |
| Surgery | 2 (1.4%) |
| None | 25 (16.9) |
↵* Patients may have more than one location.